arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

CITIUS ONCOLOGY, INC.

CTOR
$0.51 ▼ -0.04 (-6.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
22 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

CITIUS ONCOLOGY, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.0M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -21.3% ↗
FCF / Share $-0.03 ↗
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.49M
↓ -10.4% —
Net Income Profit after all expenses
$-5.53M
↑ +16.9% —
FCF / Share Free cash flow per share
$-0.03
↑ +34.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Financial Health
13
Cash Quality
30

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 22 quarters